• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by 22nd Century Group Inc.

    10/23/24 7:27:00 AM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $XXII alert in real time by email
    SC 13G 1 c110379_sc13g.htm
     
         
      SECURITIES AND EXCHANGE
    COMMISSION
     
      Washington, D.C. 20549  

     

     

     

    SCHEDULE 13G

     

    (Rule 13d-102)

     

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED

    PURSUANT TO § 240.13d-2.

     

    (Amendment No.     )*

     

    22nd Century Group Inc.

    (Name of Issuer)

     

    Common Stock, par value $0.00001 per share

    (Title of Class of Securities)

     

    90137F301

    (CUSIP Number)

     

    October 11, 2024

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    o Rule 13d-1(b)
    x Rule 13d-1(c)
    o Rule 13d-1(d)

     

     

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     
    CUSIP No: 90137F301
      (1) Names of Reporting Persons
    Iroquois Capital Management L.L.C.
      (2) Check the Appropriate Box if a Member of a Group (See Instructions)
        (a) o
        (b) o
      (3) SEC Use Only
      (4) Citizenship or Place of Organization
    Delaware
    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    (5) Sole Voting Power
    0
     
    (6)

    Shared Voting Power
    1,166,666 shares of Common Stock
    2,334,959 shares of Common Stock issuable upon exercise of Warrants (See Item 4)*

     

     
    (7) Sole Dispositive Power
    0
     
    (8)

    Shared Dispositive Power
    1,166,666 shares of Common Stock
    2,334,959 shares of Common Stock issuable upon exercise of Warrants (See Item 4)*

     

      (9)

    Aggregate Amount Beneficially Owned by Each Reporting Person
    1,166,666 shares of Common Stock
    2,334,959 shares of Common Stock issuable upon exercise of Warrants (See Item 4)*

     

      (10) Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  o
      (11) Percent of Class Represented by Amount in Row (9)
    7.29%
      (12) Type of Reporting Person (See Instructions)
    OO

     

    * As more fully described in Item 4, the Warrants are subject to a 9.99% blocker (other than certain Warrants that are subject to a 4.99% blocker) and the percentage set forth in row (11) gives effect to such blockers. However, as more fully described in Item 4, the securities reported in rows (6), (8) and (9) show the number of shares of Common Stock that would be issuable upon full exercise of such reported securities and do not give effect to such blockers. Therefore, the actual number of shares of Common Stock beneficially owned by such Reporting Person, after giving effect to such blockers, is less than the number of securities reported in rows (6), (8) and (9).

     
    CUSIP No: 90137F301
      (1) Names of Reporting Persons
    Richard Abbe
      (2) Check the Appropriate Box if a Member of a Group (See Instructions)
        (a) o
        (b) o
      (3) SEC Use Only
      (4) Citizenship or Place of Organization
    United States of America
    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    (5)

    Sole Voting Power

    2,166,667 shares of Common Stock

    4,335,772 shares of Common Stock issuable upon exercise of Warrants (See Item 4)*

     
    (6)

    Shared Voting Power
    1,166,666 shares of Common Stock

    2,334,959 shares of Common Stock issuable upon exercise of Warrants (See Item 4)*

     
    (7)

    Sole Dispositive Power
    2,166,667 shares of Common Stock
    4,335,772 shares of Common Stock issuable upon exercise of Warrants (See Item 4)*

     
    (8)

    Shared Dispositive Power
    1,166,666 shares of Common Stock
    2,334,959 shares of Common Stock issuable upon exercise of Warrants (See Item 4)*

      (9)

    Aggregate Amount Beneficially Owned by Each Reporting Person
    3,333,333 shares of Common Stock
    6,670,731 shares of Common Stock issuable upon exercise of Warrants (See Item 4)*

     

      (10) Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  o
      (11) Percent of Class Represented by Amount in Row (9)
    9.99%
      (12) Type of Reporting Person (See Instructions)
    IN; HC

     

    * As more fully described in Item 4, the Warrants are subject to a 9.99% blocker (other than certain Warrants that are subject to a 4.99% blocker) and the percentage set forth in row (11) gives effect to such blockers. However, as more fully described in Item 4, the securities reported in rows (6), (8) and (9) show the number of shares of Common Stock that would be issuable upon full exercise of such reported securities and do not give effect to such blockers. Therefore, the actual number of shares of Common Stock beneficially owned by such Reporting Person, after giving effect to such blockers, is less than the number of securities reported in rows (6), (8) and (9).

     
    CUSIP No: 90137F301
      (1) Names of Reporting Persons
    Kimberly Page
      (2) Check the Appropriate Box if a Member of a Group (See Instructions)
        (a) o
        (b) o
      (3) SEC Use Only
      (4) Citizenship or Place of Organization
    United States of America
    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    (5) Sole Voting Power
    0
     
    (6)

    Shared Voting Power
    1,166,666 shares of Common Stock
    2,334,959 shares of Common Stock issuable upon exercise of Warrants (See Item 4)*

     
    (7) Sole Dispositive Power
    0
     
    (8)

    Shared Dispositive Power
    1,166,666 shares of Common Stock
    2,334,959 shares of Common Stock issuable upon exercise of Warrants (See Item 4)*

     
      (9)

    Aggregate Amount Beneficially Owned by Each Reporting Person
    1,166,666 shares of Common Stock
    2,334,959 shares of Common Stock issuable upon exercise of Warrants (See Item 4)*

      (10) Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  o
      (11) Percent of Class Represented by Amount in Row (9)
    7.29%
      (12) Type of Reporting Person (See Instructions)
    IN

     

    * As more fully described in Item 4, the Warrants are subject to a 9.99% blocker (other than certain Warrants that are subject to a 4.99% blocker) and the percentage set forth in row (11) gives effect to such blockers. However, as more fully described in Item 4, the securities reported in rows (6), (8) and (9) show the number of shares of Common Stock that would be issuable upon full exercise of such reported securities and do not give effect to such blockers. Therefore, the actual number of shares of Common Stock beneficially owned by such Reporting Person, after giving effect to such blockers, is less than the number of securities reported in rows (6), (8) and (9).

     
    CUSIP No: 90137F301
     
    Item 1.
      (a) Name of Issuer
    22nd Century Group Inc. (the “Company”)
      (b)

    Address of Issuer’s Principal Executive Offices
    321 Farmington Road

    Mocksville, North Carolina 27028

     
    Item 2 (a). Name of Person Filing
    Item 2 (b). Address of Principal Business Office or, if none, Residence  
    Item 2 (c).

    Citizenship

    This Schedule 13G is being filed on behalf of (i) Iroquois Capital Management L.L.C., a Delaware limited liability company (“Iroquois”), (ii) Richard Abbe, an individual who is a citizen of the United States of America and (iii) Kimberly Page, an individual who is a citizen of the United States of America (“Mr. Abbe” and “Ms. Page,” together with Iroquois, the “Reporting Persons”).

     

    The Reporting Persons have entered into a Joint Filing Agreement, a copy of which is filed with this Schedule 13G as Exhibit 1, pursuant to which the Reporting Persons have agreed to file this Schedule 13G jointly in accordance with the provisions of Rule 13d-1(k) of the Securities Exchange Act of 1934, as amended.

     

    The principal business office of all of the Reporting Persons is 2 Overhill Road, Scarsdale, New York 10583.

     

    Item 2 (d)

    Title of Class of Securities
    Common Stock, par value $0.00001 per share

     

    Item 2 (e)

    CUSIP Number
    90137F301

     

     
    Item 3.

    If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    Not applicable.

      (a) o Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
      (b) o Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
      (c) o Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
      (d) o Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
      (e) o An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
      (f) o An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
     
      (g) o A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
      (h) o A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
      (i) o A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
      (j) o A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
      (k) o

    Group, in accordance with Rule 13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with

    §240.13d-1(b)(1)(ii)(J), please specify the type of
    institution:____________________________

     

    Item 4. Ownership

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

    The information as of the date of the event which requires filing of this statement required by Items 4(a) – (c) is set forth in Rows 5 – 11 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person. The percentage set forth in Row 11 of the cover page for each Reporting Person is based on 45,702,624 shares of Common Stock issued and outstanding as represented in the Company’s Prospectus Supplement filed pursuant to Rule 424(b)(5) with the Securities and Exchange Commission on October 15, 2024 and assumes the completion of the offering of 14,266,666 shares of Common Stock described therein, and further assumes the exercise of the Company’s reported warrants (collectively, the “Reported Warrants”), each subject to the Blockers (as defined below)

     

    Pursuant to the terms of the Reported Warrants, the Reporting Persons cannot exercise the Reported Warrants to the extent the Reporting Persons would beneficially own, after any such exercise, more than 9.99% (other than certain Warrants that are subject to a 4.99% blocker) of the outstanding shares of Common Stock (collectively, the “Blockers”), and the percentage set forth in Row 11 of the cover page for each Reporting Person gives effect to the Blockers, if applicable.

     

    As of the date of the event which requires filing of this statement, Iroquois Master Fund Ltd. (“Iroquois Master Fund”) held 1,166,666 shares of Common Stock and Reported Warrants to purchase 2,334,959 shares of Common Stock (subject to the Blockers), and Iroquois Capital Investment Group LLC (“ICIG”) held 2,166,667 shares of Common Stock and Reported Warrants to purchase 4,335,772 shares of Common Stock (subject to the Blockers).

     

    Mr. Abbe shares authority and responsibility for the investments made on behalf of Iroquois Master Fund with Ms. Kimberly Page, each of whom is a director of the Iroquois Master Fund. As such, Mr. Abbe and Ms. Page may each be deemed to be the beneficial owner of all shares of Common Stock held by and underlying the Reported Warrants (each subject to the Blockers) held by, Iroquois Master Fund. Iroquois Capital is the investment advisor for Iroquois Master Fund and Mr. Abbe is the President of Iroquois Capital. Mr. Abbe has the sole authority and responsibility for the investments made on behalf of ICIG. As such, Mr. Abbe may be deemed to be the beneficial owner of all shares of Common Stock held by and underlying the Reported Warrants (each subject to the Blockers) held by, Iroquois Master Fund and ICIG. The foregoing should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of shares of Common Stock owned by another Reporting Person. Each of the Reporting Persons hereby disclaims any beneficial ownership of any such shares of Common Stock except to the extent of their pecuniary interest therein.

     
    Item 5. Ownership of Five Percent or Less of a Class
       
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following:   o

     

    Item 6.        Ownership of More than Five Percent on Behalf of Another Person
       
    Not applicable.
     
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person

     

    Not applicable.

     

    Item 8. Identification and Classification of Members of the Group

     

    See Exhibit 1.

     

    Item 9. Notice of Dissolution of Group

     

    Not applicable.

     

    Item 10. Certification

     

    By signing below each of the undersigned certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

       

    SIGNATURES

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: October 23, 2024

     

      IROQUOIS CAPITAL MANAGEMENT L.L.C.
                           
      By: /s/ Richard Abbe  
        Richard Abbe, President  
           
      /s/ Richard Abbe  
      Richard Abbe  
           
      /s/ Kimberly Page  
      Kimberly Page  
       

    EXHIBIT INDEX

     

    Exhibit 1 Joint Filing Agreement as required by Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended.
       
    Get the next $XXII alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $XXII

    DatePrice TargetRatingAnalyst
    7/21/2022$5.00Buy
    Alliance Global Partners
    6/15/2022$5.00Buy
    Craig Hallum
    3/8/2022$6.00Buy
    Roth Capital
    7/23/2021$5.00Outperform
    Cowen
    More analyst ratings

    $XXII
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Alliance Global Partners initiated coverage on 22nd Century Group with a new price target

    Alliance Global Partners initiated coverage of 22nd Century Group with a rating of Buy and set a new price target of $5.00

    7/21/22 9:12:19 AM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    Craig Hallum initiated coverage on 22nd Century Group with a new price target

    Craig Hallum initiated coverage of 22nd Century Group with a rating of Buy and set a new price target of $5.00

    6/15/22 7:42:24 AM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    Roth Capital initiated coverage on 22nd Century Group with a new price target

    Roth Capital initiated coverage of 22nd Century Group with a rating of Buy and set a new price target of $6.00

    3/8/22 9:21:23 AM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    $XXII
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Keys David N

    3 - 22nd Century Group, Inc. (0001347858) (Issuer)

    8/5/25 4:55:06 PM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    Director Johnson Anthony L. was granted 2,472 shares, increasing direct ownership by 35,314% to 2,479 units (SEC Form 4)

    4 - 22nd Century Group, Inc. (0001347858) (Issuer)

    3/12/25 5:37:14 PM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    Director Salhany Lucille S was granted 2,472 shares, increasing direct ownership by 49,440% to 2,477 units (SEC Form 4)

    4 - 22nd Century Group, Inc. (0001347858) (Issuer)

    3/12/25 5:35:14 PM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    $XXII
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Firestone Lawrence bought $10,468 worth of shares (39,000 units at $0.27), increasing direct ownership by 256% to 54,250 units (SEC Form 4)

    4 - 22nd Century Group, Inc. (0001347858) (Issuer)

    9/12/24 5:00:14 PM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    Firestone Lawrence bought $9,829 worth of shares (9,000 units at $1.09), increasing direct ownership by 144% to 15,250 units (SEC Form 4)

    4 - 22nd Century Group, Inc. (0001347858) (Issuer)

    5/31/24 4:05:20 PM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    Arno Andrew bought $17,490 worth of shares (100,000 units at $0.17) (SEC Form 4)

    4 - 22nd Century Group, Inc. (0001347858) (Issuer)

    1/8/24 8:04:11 PM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    $XXII
    SEC Filings

    View All

    22nd Century Group Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits

    8-K - 22nd Century Group, Inc. (0001347858) (Filer)

    8/26/25 5:15:29 PM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 424B5 filed by 22nd Century Group Inc.

    424B5 - 22nd Century Group, Inc. (0001347858) (Filer)

    8/26/25 4:30:41 PM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form S-8 filed by 22nd Century Group Inc.

    S-8 - 22nd Century Group, Inc. (0001347858) (Filer)

    8/15/25 5:25:39 PM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    $XXII
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    December 23, 2021 - FDA Authorizes Marketing of Tobacco Products that Help Reduce Exposure to and Consumption of Nicotine for Smokers Who Use Them

    For Immediate Release: December 23, 2021 Today, the U.S. Food and Drug Administration authorized the marketing of 22nd Century Group Inc.’s “VLN King” and “VLN Menthol King” combusted, filtered cigarettes as modified risk tobacco products (MRTPs), which help reduce exposure to, and consumption of, nicotine for smokers who use them. These are the first combusted cigarettes to be authorized as MRTPs and the second

    12/23/21 9:06:12 AM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    $XXII
    Leadership Updates

    Live Leadership Updates

    View All

    22nd Century Announces First Shipments of Pinnacle VLN® Products to Top 5 C-Store Chain Locations Across 12 States

    Pinnacle VLN® from 22nd Century Gains 2nd Early Adopter to Join Popular Pinnacle Branded Conventional Cigarette Products Already Sold at Top-5 U.S. C-Store Chain MOCKSVILLE, N.C., Aug. 04, 2025 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), the only tobacco products company that has for 27 years led and continues to lead the fight against the harms of smoking driven by nicotine addiction, today announced the first shipments of its new Pinnacle VLN® Gold and Pinnacle VLN® Menthol reduced nicotine content cigarettes into distribution. These initial Pinnacle VLN® shipments will support a sales launch expected on September 1, 2025 at almost 1,000 locations across 12 states for a

    8/4/25 8:00:00 AM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    22nd Century Announces Resignation of John Miller as President of Tobacco

    Helped Establish National Scale Distribution and Launch VLN in More Than 5,000 Stores Across the CountryMocksville, North Carolina--(Newsfile Corp. - May 30, 2024) - 22nd Century Group, Inc. (NASDAQ:XXII), a tobacco products company focused on nicotine harm reduction, today announced that John Miller has resigned as President of Tobacco, effective August 2, 2024. Said Larry Firestone, Chairman and CEO: "I want to thank John for the pivotal role he played in the launch of VLN®, leveraging his decades of industry experience to help us achieve national-scale distribution and establishing a retail presence in more than 5,000 stores across 26 states. He also played a key role in expanding our CMO

    5/30/24 4:05:00 PM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    22nd Century Group (Nasdaq: XXII) Appoints Accomplished Media Executive Lucille S. Salhany to Its Board

    BUFFALO, N.Y., Sept. 12, 2022 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), a leading agricultural biotechnology company dedicated to improving health with reduced nicotine tobacco, hemp/cannabis, and hops advanced plant technologies, today announced the appointment of Lucie S. Salhany to its Board of Directors. Ms. Salhany is a highly accomplished media executive with extensive experience in assessing and understanding the consumer landscape, positioning unique products for successful launch utilizing digital media, corporate strategy, and entrepreneurial ventures. She is widely recognized for her appointment as the first woman chair of a major broadcast network, which was e

    9/12/22 4:05:00 PM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    $XXII
    Financials

    Live finance-specific insights

    View All

    22nd Century Group Reports Second Quarter 2025 Financial Results

    VLN® Early Adoption Commercial Activity Expands with Two Partner Brand Launches in Progress – Smoker Friendly and Pinnacle Commenced Pinnacle VLN® Stocking Shipments for Almost 1,000 Locations of Top-5 C-Store Customer, Additional Locations to Come Significantly Expanded State Authorizations for both Reduced Nicotine Content and Conventional Products High Margin Branded Products Business Model Set to Grow Profitably MOCKSVILLE, N.C., Aug. 14, 2025 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), the only tobacco products company that has for 27 years led and continues to lead the fight against the harms of smoking driven by nicotine addiction, today announced results for th

    8/14/25 6:00:00 AM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    22nd Century Group Reports First Quarter 2025 Financial Results

    Sales Increase Approximately 50% Sequentially as 2025 Growth Strategy Drives New Sales Activity with Both Internal and External Brand Assets Across Multiple Categories  Preparing First VLN® Partner Brand Shipments with Smoker Friendly and Others Filings Made for New Reduced Nicotine Content and Conventional Product Authorizations in All 50 States Launch of Smoker Friendly Black Label – Tobacco and Water natural style cigarettes MOCKSVILLE, N.C., May 13, 2025 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), a tobacco products company that is leading the fight against nicotine dependence and believes smokers should have a choice about their nicotine consumption, today announ

    5/13/25 6:00:00 AM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    22nd Century Group Completes Sale of Needle Rock Farms Assets

    Further Strengthens Balance Sheet Cash Position MOCKSVILLE, N.C., May 08, 2025 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), a tobacco products company that is leading the fight against nicotine dependence and believes smokers should have a choice about their nicotine consumption, today announced closing of the sale of its Needle Rock Farms assets with net proceeds of approximately $770,000 after expenses. "The sale of unused assets such as Needle Rock Farms which was related to the hemp cannabis business that was sold in December 2023, enables us to redeploy capital into our current growth plans," said Larry Firestone, CEO of 22nd Century Group. "The additional $770,000 in

    5/8/25 5:07:00 PM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    $XXII
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Presenting on Emerging Growth Conference 85 Day 2 on August 21; Register to live stream

    MIAMI, Aug. 20, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 85th Emerging Growth Conference on August 20 & 21, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: [email protected] For updates, follow us on Twitter Day 1 – Presenting Today, August 20, 2025 8:45Virtual Lobby opens.Register for the Conference. If you already registered

    8/20/25 7:00:00 AM ET
    $ADVM
    $CLNN
    $DERM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Diversified Commercial Services

    22nd Century CEO & Chairman Larry Firestone Provides Technology and Regulatory Update Letter to Stockholders

    MOCKSVILLE, N.C., Aug. 20, 2025 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), a tobacco products company that has for 27 years led and continues to lead the fight against the harms of smoking driven by nicotine addition, today issued the following letter to stockholders from Larry Firestone, the Chief Executive Officer of 22nd Century Group, Inc.:  A Letter to Our Shareholders We recently released our second quarter 2025 earnings, along with important corporate updates regarding the ongoing launch and rollout of VLN® products. VLN® cigarettes are the first and only combustible tobacco product purposefully designed to reduce the harms of smoking and authorized by the U.S. Fo

    8/20/25 7:00:00 AM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    Presenting on Emerging Growth Conference 85 Day 1 on August 20; Register to live stream

    MIAMI, Aug. 19, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 85th Emerging Growth Conference on August 20 & 21, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: [email protected] For updates, follow us on Twitter. Day 1August 20, 2025 8:45Virtual Lobby opens.Register for the Conference. If you already registered, go back to the reg

    8/19/25 7:00:00 AM ET
    $ADVM
    $CLNN
    $DERM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Diversified Commercial Services

    $XXII
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by 22nd Century Group Inc.

    SC 13G/A - 22nd Century Group, Inc. (0001347858) (Subject)

    12/3/24 11:18:54 AM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    Amendment: SEC Form SC 13G/A filed by 22nd Century Group Inc.

    SC 13G/A - 22nd Century Group, Inc. (0001347858) (Subject)

    11/14/24 5:56:57 PM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G filed by 22nd Century Group Inc.

    SC 13G - 22nd Century Group, Inc. (0001347858) (Subject)

    10/23/24 7:27:00 AM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care